Hence, using only the KRAS mutation to confirm tumor identity with the primary tissue may not be sufficient, and may require the addition of other genetic mutations such as TP53, SMAD4, and/or CDKN2A which together account for the top four mutations observed in PDAC [129]. This evidence concerns the gene KRAS and neoplasm.